loading
loading
Laurus Labs Q2 Results: Profit more than doubles, margin beats estimates; dividend declared - Published OnOct 29, 2026 | 15:20 IST - Last Updated OnOct 29, 2026 | 15:20 IST Laurus Labs’ September-quarter profit more than doubled, beating estimates alongside revenue and EBITDA. The company also approved acquisitions of a Canadian biotech firm and a polymer products maker. Laurus Labs reported a strong set of results for the September quarter, with net profit more than doubling year-on-year and revenue and operating earnings comfortably beating CNBC-TV18’s estimates. The pharmaceutical company also announced plans to acquire controlling stakes in two businesses, including a Canada-based biotech firm, and declared an interim dividend of ₹1 per share. Net profit rose 126.7% year-on-year to ₹442 crore in Q2 FY27, compared with ₹195 crore a year ago. The figure was also well ahead of CNBC-TV18’s poll estimate of ₹354.1 crore. Revenue from operations grew 33.4% to ₹2,206 crore from ₹1,653.5 crore in the year-ago quarter, surpassing the estimate of ₹2,109.5 crore. Earnings before interest, tax, depreciation and amortisation (EBITDA) jumped 86% year-on-year to ₹750 crore, against ₹403.3 crore a year earlier. This was higher than the poll estimate of ₹644.4 crore. EBITDA margin expanded to 34% from 24.4% a year ago, also beating the estimate of 30.5%. Shares of Laurus Labs were trading 2.14% higher at ₹2,231.80 on the BSE following the earnings announcement. Laurus Labs to acquire stakes in two companies Separately, Laurus Labs’ board approved the acquisition of a 52% stake in SI & C Resins Private Limited at a pre-money valuation of ₹30 crore. The company plans to invest ₹32.5 crore in the transaction, which will make SI&C a subsidiary. SI&C manufactures polymer- and silica-based products for the chemical, pharmaceutical and biotechnology industries. Laurus Labs may also invest up to an additional ₹30 crore in securities issued by SI&C as and when the company requires funds. The board also approved the acquisition of a 60% stake in Canada-based Galenvs Sciences Inc. at a pre-money valuation of $3.5 million. Laurus Labs proposes to invest $3.75 million, comprising a primary infusion of $2.75 million and a secondary acquisition worth $1 million from the founder shareholder. Galenvs is a contract research and development organisation specialising in custom oligonucleotide synthesis and functional magnetic nanoparticle technologies for diagnostic and therapeutic applications. Its subsidiary, Galenvs Solutions Inc., will become a step-down subsidiary of Laurus Labs following the acquisition. ₹1 interim dividend declared Laurus Labs’ board also approved an interim dividend of ₹1 per equity share of ₹2 face value for FY27. The company has fixed November 6, 2026, as the record date to determine shareholder eligibility. The dividend will be paid on or after November 19, 2026.
document fetched 2026-10-30 02:56 · canonical https://cnbctv18.com/market/earnings/laurus-labs-q2-results-profit-more-than-doubles-margin-beats-estimates-dividend-declared-20022444.htm